Savara Inc. (SVRA)Healthcare | Biotechnology | Yardley, United States | NasdaqGS
5.74 USD
-0.29
(-4.809%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 5.74 |
Hot Take ↕ | July 11, 2026, 5:55 a.m. EDT
Savara presents a stark dichotomy between a resilient recent price trend and a fundamentally deteriorating business. While the stock has rallied significantly over the last year, the underlying reality is grim: the company is burning cash aggressively with negative free cash flow and operating cash flow, and its return on equity is deeply negative. The balance sheet is fragile, with debt-to-equity exceeding 17x, and the company recently raised capital through a public offering, a classic sign of liquidity stress. The recent rally appears to be a temporary reprieve driven by regulatory milestones rather than a turnaround in profitability. The options market confirms this skepticism, with traders loading up on puts to protect against further declines. Without a clear path to profitability or a massive commercial breakthrough, the long-term outlook remains severely compromised. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.052124 |
| AutoARIMA | 0.056172 |
| AutoETS | 0.060241 |
| MSTL | 0.061450 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 10.97 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.037 |
| Excess Kurtosis | 0.20 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 17.105 |
| Market Cap | 1,176,282,112 |
| Forward P/E | -19.52 |
| Beta | 0.24 |
| Website | https://www.savarapharma.com |
As of July 11, 2026, 5:55 a.m. EDT: Speculators are positioning defensively with heavy put volume relative to calls, particularly in the November and February expirations where out-of-the-money puts show significant new flow. This indicates a fear of further downside or a lack of conviction in a recovery, despite the stock trading near its 52-week highs recently. Implied volatility is extremely low across all strikes, suggesting the market expects minimal movement and views the asset as low probability for a catalyst-driven surge.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.4023905 |
| Address1 | The Tannery |
| Address2 | Suite 200 19 W. College Avenue West College Avenue |
| All Time High | 17.187 |
| All Time Low | 0.69 |
| Ask | 7.28 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 2,188,390 |
| Average Daily Volume3 Month | 1,614,891 |
| Average Volume | 1,614,891 |
| Average Volume10Days | 2,188,390 |
| Beta | 0.242 |
| Bid | 4.27 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 0.694 |
| City | Yardley |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.74 |
| Current Ratio | 13.467 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 5.92 |
| Day Low | 5.66 |
| Debt To Equity | 17.105 |
| Display Name | Savara |
| Dividend Date | 1,493,337,600 |
| Earnings Timestamp End | 1,778,675,400 |
| Earnings Timestamp Start | 1,778,675,400 |
| Ebitda | -133,168,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -9.621 |
| Enterprise Value | 1,281,185,280 |
| Eps Current Year | -0.58 |
| Eps Forward | -0.294 |
| Eps Trailing Twelve Months | -0.56 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.4118 |
| Fifty Day Average Change | 0.32819986 |
| Fifty Day Average Change Percent | 0.060645234 |
| Fifty Two Week Change Percent | 140.23904 |
| Fifty Two Week High | 7.005 |
| Fifty Two Week High Change | -1.2650003 |
| Fifty Two Week High Change Percent | -0.18058534 |
| Fifty Two Week Low | 2.25 |
| Fifty Two Week Low Change | 3.4899998 |
| Fifty Two Week Low Change Percent | 1.551111 |
| Fifty Two Week Range | 2.25 - 7.005 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,493,386,200,000 |
| Float Shares | 130,117,812 |
| Forward Eps | -0.294 |
| Forward P E | -19.52381 |
| Free Cashflow | -57,653,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 70 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -81,404,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02575 |
| Held Percent Institutions | 1.04217 |
| Implied Shares Outstanding | 204,927,212 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania. |
| Long Name | Savara Inc. |
| Market | us_market |
| Market Cap | 1,176,282,112 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_59211637 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -129,482,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,235,711,088 |
| Number Of Analyst Opinions | 8 |
| Open | 5.92 |
| Operating Cashflow | -106,894,000 |
| Operating Margins | 0.0 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 5.74 |
| Post Market Time | 1,783,981,117 |
| Previous Close | 6.03 |
| Price Eps Current Year | -9.896552 |
| Price Hint | 2 |
| Price To Book | 8.270893 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.205 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.29 |
| Regular Market Change Percent | -4.80929 |
| Regular Market Day High | 5.92 |
| Regular Market Day Low | 5.66 |
| Regular Market Day Range | 5.66 - 5.92 |
| Regular Market Open | 5.92 |
| Regular Market Previous Close | 6.03 |
| Regular Market Price | 5.74 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,642,388 |
| Return On Assets | -0.4053 |
| Return On Equity | -0.79955 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 204,927,212 |
| Shares Percent Shares Out | 0.15630001 |
| Shares Short | 32,028,140 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 30,192,189 |
| Short Name | Savara, Inc. |
| Short Percent Of Float | 0.18270001 |
| Short Ratio | 15.35 |
| Source Interval | 15 |
| State | PA |
| Symbol | SVRA |
| Target High Price | 16.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 10.9375 |
| Target Median Price | 10.25 |
| Total Cash | 204,144,000 |
| Total Cash Per Share | 0.805 |
| Total Debt | 30,111,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.2511 |
| Two Hundred Day Average Change | 0.4888997 |
| Two Hundred Day Average Change Percent | 0.09310424 |
| Type Disp | Equity |
| Volume | 1,642,388 |
| Website | https://www.savarapharma.com |
| Zip | 19,067 |